Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-038 phase 2 study in complement-mediated kidney disease
2025-521752-26-00Phase 2Authorised
- Sponsor
- ADARx Pharmaceuticals
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of agazisiran in complement-mediated kidney disease, IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G) and 1 more, sponsored by ADARx Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Apr 2026; status: authorised.
02
Drugs
agazisiran
03
Conditions
complement-mediated kidney diseaseIgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2025-521752-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521752-26-00.